Prevention of renal impairment by continuous infusion of human atrial natriuretic peptide after liver transplantation

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

Acute renal failure occurring immediately after liver transplantation and requiring hemodialysis is a major problem resulting in a poor prognosis.

Who Took Part

According to the abstract, 15 subjects were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Thirty-seven patients who underwent live donor liver transplantation with model for end-stage liver disease scores greater than 15 were the subjects of the study.

Subjects were prospectively randomized into two groups: patients that received synthetic human atrial natriuretic peptide infusion (Group H: n=19) and those that received conventional diuretics, furosemide and potassium canrenoate (Group C: n=18).

How the Study Was Run

The design is described as randomized.

The subjects were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

The peri- and postoperative changes in hemodynamic status and renal function were compared between the two groups.

What Was Measured

Topics PubMed links to this paper include Acute Kidney Injury, Aldosterone, Atrial Natriuretic Factor, Diuretics, Hemodynamics, Intraoperative Care and Liver Failure.

What This Means in Plain Language

The paper is a randomized study of ANP (Atrial Natriuretic Peptide) in 15 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Transplantation), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.